Goldman Small Cap Research

07/17/2025

Today we published a report and video on an innovative company that is developing a treatment for a life-threatening side effect of chemotherapy. Regen BioPharma Inc. (OTC:RGBP) is set to go from the preclinical stage to Phase I clinical trials for their stem cell-derived therapy to treat this condition, known as severe aplastic anemia (SAA). It is a $1 billion market and Regen has a deep pipeline and IP portfolio so we expect a great deal of performance from these undervalued and underfollowed shares. Companies typically get a big bump in value when they have an active Phase I trial.

See why one feature of this therapy could be a boon for the Company!
https://goldmansmallcapresearch.com/opportunity-research/regen-phase-i/
https://youtu.be/Sr8wmOXcfPQ?si=snhEoBxGO8G-VtKB

RGBP: Phase I Clinical Trial Candidate to Drive Valuation Higher Posted on July 17, 2025July 17, 2025 by admin RGBP: Phase I Clinical Trial Candidate to Drive Valuation Higher Investment and Company Research Opportunity Research COMPANY REPORT July 17, 2025 REGEN BIOPHARMA, INC. (OTC – RGBP) Indus...

07/08/2025

We published a report and video on a clean energy integrator poised to become a major player in upstate New York. Acadia Energy (OTC:AECX) is a great story and has exciting milestones ahead.

https://youtu.be/3GWGbfs17Qw?si=Amln5Uod9Jg_liBj

https://goldmansmallcapresearch.com/opportunity-research/aecx-clean-energy/

08/24/2023

AI stocks are the hottest segment of the market and for good reason. A new report is out today on an under the radar AI firm abt to surge higher as well. Sybleu (Ticker: SYBE) is an AI-driven drug discovery firm in the lucrative vet health market. This industry segment has peers that boast huge valuations ranging from 27x - 100x revenue---and it looks like SYBE is on the same path as it reaches a series of milestones in the coming months. Investors have an insatiable appetite for these stocks and continue to raise hundreds of millions for them. That is why we believe SYBE could join the party by year-end.

Emerging AI-Driven Biotech Sybleu, Inc. (OTC:SYBE) offers competitive advantages and upcoming milestones in the stock market's top-followed and funded segment, AI, prompting a potential surge in the s

08/17/2023

PUR Biologics, the primary medtech subsidiary of HippoFi, Inc. (Ticker: ORHB) is hitting the ball out of the park. In just the past few months, the company had its biologics products used in spinal surgeries for bone regeneration approved for use in the entire VA health network---that's 171 medical centers and 1,113 outpatient sites serving millions of veterans. Plus, military bases. ORHB has also signed a deal to join forces w/an industry giant, introduced new products, and was awarded 2 new breakthrough patents. The stock appears to be a great entry point as the outcomes of these events should result in major price gains.

In what may be the best kept secret on Wall Street, emerging MedTech Firm HippoFi, Inc. (OTC:ORHB) is experiencing unprecedented sales growth. And that's just part of this innovator's story.

08/17/2023

New report on award-winning smart gym equip maker and digital health services co. Interactive Strength, Inc. d/b/a FORME (NASDAQ: TRNR). Co. just signed an LOI for an acquisition that we believe is transformative for TRNR. It will dramatically accelerate high rev growth/profit. Thus, the deal could lead to major stock gains ahead. TRNR closed @ $1.23, trades only 0.7x sales--artificially low valuation. Now a great entry point. Our target is $4.15, and reflects a reasonable 3x 2024E sales.

Interactive Strength, Inc. (NASDAQ: TRNR) d/b/a FORME is about to make a profound change in its business that will prompt major growth, accelerate profit, and drive the artificially low valuation subs

08/14/2023

We have published new report out on The Healing Company (Ticker: HLCO), the next health and wellness unicorn. HLCO has a strong relationship with Deepak Chopra, who is the Chief Scientific Officer. The company also owns and operates Chopra Global which boasts a huge following, especially on social media. There are a series of acq deals ahead & a $150M M&A credit facility to draw down on which are poised to drive major sales growth. Plus, a NASDAQ uplisting in the cards. We currently have a $9 tgt price.

Leveraging a $150M M&A-targeted credit facility, and a core relationship with Deepak Chopra, integrated health firm The Healing Company, Inc. (OTCQB: HLCO) is poised to record exponential revenue grow

05/05/2023

New report on a company undergoing a major transformation--driving annual rev growth from $162M in 2022 to $913M in 2023, with $0.30 in adjusted EPS. Muscle Maker Inc. (NASDAQ:GRIL) is fast becoming a major player in the global food supply chain, with 2 distinct business lines. Our 6-9 month conservative target is 3x recent prices, with more potential upside in the cards. Given its rapid transformation, and huge growth, GRIL could be the most talked about play on NASDAQ this year.

Muscle Maker, Inc. (NASDAQ: GRIL) is set to grow revenue from $162M in 2022 to over $1B in 2024, with a substantial rise in adjusted net income, thereby driving its share price to new highs

04/24/2023

ICYMI...HippoFi, Inc. (ORHB) was one of the biggest movers in the stock market last week, right after we issued our report on the company. ORHB is a fast-growing, underfollowed medtech company that offers considerable upside. Check it out here:

In what may be the best kept secret on Wall Street, emerging MedTech Firm HippoFi, Inc. (OTC:ORHB) is experiencing unprecedented sales growth. And that's just part of this innovator's story.

04/20/2023

Wall Street's best kept secret!

We have just published a new report on HippoFi, Inc. (ORHB). It is an undervalued, underfollowed medtech provider that is experiencing unprecedented sales growth. This innovative company offers major upside, based on the values placed on its lower growth peers. As word gets out, and upcoming financials are released, we would not be surprised to see aggressive accumulation.

In what may be the best kept secret on Wall Street, emerging MedTech Firm HippoFi, Inc. (OTC:ORHB) is experiencing unprecedented sales growth. And that's just part of this innovator's story.

04/13/2023

We have a new report on fast-growing consumer disc stock Charlie's Holdings (CHUC). The company is very undervalued compared to its slower-growth, larger peers--a gap we believe will narrow this year given that sales could jump by more than 60%, from $26.5M to $44M along with a potentially strong income performance. Our near term target price is 3x higher than the previous close. Check it out here: https://bit.ly/3GF18V5

03/28/2023

Good morning! We have an exciting new report our today on Camber Energy, Inc.: CEI on the NYSE. CEI may be the most diversified energy and power generation technology stock we've seen in some time. This undervalued co is set to close a merger with Viking Energy Group (VKIN) in 2H23 that serves as a catalyst to drive the combined companies' sales and CEI markedly higher. Check it out here:

The Camber Energy, Inc. (NYSE: CEI) pending merger with Viking Energy Group Inc. (OTC:VKIN) could drive CEI's market cap much higher as the combined company would emerge as one of the most diverse ene